| 4.02 0.28 (7.49%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.82 | 1-year : | 5.63 |
| Resists | First : | 4.13 | Second : | 4.82 |
| Pivot price | 3.65 |
|||
| Supports | First : | 3.56 | Second : | 3.21 |
| MAs | MA(5) : | 3.78 |
MA(20) : | 3.66 |
| MA(100) : | 3.86  |
MA(250) : | 4.12 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 73.4 |
D(3) : | 60.9 |
| RSI | RSI(14): 56.4 |
|||
| 52-week | High : | 8.82 | Low : | 1.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FATE ] has closed below upper band by 1.5%. Bollinger Bands are 51.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.02 - 4.04 | 4.04 - 4.05 |
| Low: | 3.76 - 3.78 | 3.78 - 3.79 |
| Close: | 3.99 - 4.02 | 4.02 - 4.05 |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Thu, 12 Sep 2024
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference - GlobeNewswire
Thu, 12 Sep 2024
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? - Yahoo Finance
Thu, 12 Sep 2024
Acadian Asset Management LLC Acquires 294,738 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Fri, 30 Aug 2024
Fate Therapeutics updates indemnification agreements - Investing.com
Fri, 30 Aug 2024
Fate Therapeutics Strengthens Legal Safeguards for Leadership - TipRanks
Thu, 15 Aug 2024
Fate Therapeutics Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 114 (M) |
| Shares Float | 90 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 108.8 (%) |
| Shares Short | 13,930 (K) |
| Shares Short P.Month | 20,290 (K) |
| EPS | -1.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.49 |
| Profit Margin | 0 % |
| Operating Margin | -665.8 % |
| Return on Assets (ttm) | -20.5 % |
| Return on Equity (ttm) | -42.1 % |
| Qtrly Rev. Growth | 625.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.1 |
| EBITDA (p.s.) | -1.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -141 (M) |
| Levered Free Cash Flow | -67 (M) |
| PE Ratio | -2.37 |
| PEG Ratio | 0 |
| Price to Book value | 1.15 |
| Price to Sales | 37.15 |
| Price to Cash Flow | -3.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|